# Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".

> **NCT02489331** · — · COMPLETED · sponsor: **Abbott** · enrollment: 193 (actual)

## Conditions studied

- Dyslipidemias

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02489331
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2020-11-10
- **Final completion:** 2020-11-10
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2020-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489331, "Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the "New Drug Re-examination".". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02489331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*